Brokerages Set KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) PT at $30.60

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) has been given an average rating of “Hold” by the nine research firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $30.60.

KALV has been the subject of a number of research reports. Leerink Partners lowered shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 29th. Wall Street Zen upgraded shares of KalVista Pharmaceuticals to a “hold” rating in a report on Saturday, June 13th. JonesTrading downgraded shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, April 30th. Weiss Ratings restated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Tuesday, April 21st. Finally, HC Wainwright lowered shares of KalVista Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the company from $37.00 to $27.00 in a research report on Friday, May 1st.

Insider Transactions at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, CFO Brian Piekos sold 1,862 shares of the business’s stock in a transaction dated Friday, April 17th. The shares were sold at an average price of $20.22, for a total value of $37,649.64. Following the transaction, the chief financial officer directly owned 18,150 shares in the company, valued at $366,993. The trade was a 9.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, major shareholder Venrock Healthcare Capital Par sold 174,645 shares of the business’s stock in a transaction dated Wednesday, March 25th. The shares were sold at an average price of $16.95, for a total transaction of $2,960,232.75. Following the completion of the transaction, the insider owned 5,129,340 shares in the company, valued at approximately $86,942,313. This trade represents a 3.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 254,602 shares of company stock valued at $4,656,670. 4.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On KalVista Pharmaceuticals

A number of institutional investors have recently modified their holdings of KALV. Parallel Advisors LLC raised its position in KalVista Pharmaceuticals by 45.8% in the 1st quarter. Parallel Advisors LLC now owns 1,876 shares of the specialty pharmaceutical company’s stock worth $38,000 after purchasing an additional 589 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in KalVista Pharmaceuticals by 5.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 14,626 shares of the specialty pharmaceutical company’s stock worth $165,000 after purchasing an additional 818 shares during the last quarter. BNP Paribas Financial Markets raised its position in KalVista Pharmaceuticals by 47.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after purchasing an additional 1,292 shares during the last quarter. Rhumbline Advisers raised its position in KalVista Pharmaceuticals by 2.8% in the 2nd quarter. Rhumbline Advisers now owns 54,376 shares of the specialty pharmaceutical company’s stock worth $615,000 after purchasing an additional 1,458 shares during the last quarter. Finally, Royal Bank of Canada raised its position in KalVista Pharmaceuticals by 137.0% in the 1st quarter. Royal Bank of Canada now owns 2,917 shares of the specialty pharmaceutical company’s stock worth $59,000 after purchasing an additional 1,686 shares during the last quarter.

KalVista Pharmaceuticals Stock Performance

KalVista Pharmaceuticals stock opened at $27.00 on Monday. The company has a 50 day moving average price of $24.87 and a 200 day moving average price of $19.29. KalVista Pharmaceuticals has a 52 week low of $9.83 and a 52 week high of $27.00. The company has a debt-to-equity ratio of 8.18, a quick ratio of 5.10 and a current ratio of 5.17. The firm has a market capitalization of $1.44 billion, a price-to-earnings ratio of -7.80 and a beta of -0.12.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings data on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). The company had revenue of $40.86 million for the quarter, compared to analysts’ expectations of $39.03 million. Research analysts forecast that KalVista Pharmaceuticals will post -1.19 EPS for the current year.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical?stage biotechnology company focused on the discovery and development of small?molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.